Intracoronary infusion of bone marrow cells two to three weeks post-MI doesn't better LV function
TUESDAY, Nov. 15 (HealthDay News) -- Intracoronary infusion of bone marrow mononuclear cells (BMCs) two to three weeks after myocardial infarction (MI) in patients with significant left ventricular (LV) dysfunction after percutaneous coronary intervention (PCI), does not improve global (LVEF) or regional (wall motion) LV function, according to a study published in the cardiovascular disease-themed Nov. 16 issue of the Journal of the American Medical Association to coincide with presentation at the American Heart Association's Scientific Sessions 2011, held from Nov. 12 to 16 in Orlando, Fla.
Jay H. Traverse, M.D., from the Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, and colleagues investigated whether intracoronary delivery of autologous BMCs two to three weeks after first MI improved LVEF and wall motion compared to placebo in 87 patients with significant LV dysfunction (ejection fraction [EF], ≤45 percent) who underwent PCI between July 2008 and February 2011. The difference in LVEF and wall motion in the infarct and border zone between baseline and six-months was the primary end point. Changes in LV volumes and infarct size were the secondary end points.
The investigators found that harvesting, processing, and intracoronary BMC delivery were feasible. There was no statistically significant difference in the baseline to six-month between-group mean difference in the LVEF or wall motion in the infarct or in the border zone. Baseline to six-month changes in LV and infarct volume between the two groups were similar and non-significant.
"BMC delivery two to three weeks following MI resulted in no detectable improvement in LV function," the authors write.
One of the study authors disclosed financial ties to the biotechnology industry.
Editorial (subscription or payment may be required)